[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100470895":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":12,"centralContacts":28,"locations":37,"responsibleParty":51,"collaborators":12,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":12,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":12,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":12,"overallStatus":71,"whyStopped":12,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Peking University Third Hospital","OTHER",[8,13,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm1","NO_INTERVENTION","The ctDNA is positive after SBRT and no adjuvant therapy is used after SBRT.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Arm 2","EXPERIMENTAL","The ctDNA is positive after SBRT and adjuvant therapy is used after SBRT.",[18],"Drug: drug adjuvant therapy",{"label":20,"type":10,"description":21,"interventionNames":12},"Arm 3","The ctDNA is negative after SBRT and no adjuvant therapy is used after SBRT.",[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":12},"DRUG","drug adjuvant therapy","The adjuvant treatment regimens depend on the judgment of oncology physicians according to pathological type, molecular characteristics and other details of the tumor.",[14],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":12,"email":33},"Hongqing Zhuang","CONTACT","82264910","hongqingzhuang@163.com",{"name":35,"role":31,"phone":32,"phoneExt":12,"email":36},"Yuxia Wang","Lily31415926@126.com",[38],{"facility":39,"status":12,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":12},"Department of Radiation Oncology Cancer Center, Peking University Third Hospital 49# North Garden Rd.,Haidian Dist.","Beijing","Beijing Municipality","100191","China","CN",{"type":46,"coordinates":47},"Point",[48,49],116.39723,39.9075,{"lat":49,"lon":48},{"type":52,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100470895","the-ctdna-for-evaluating-whether-to-use-adjuvant-therapy-after-sbrt-in-patients-with-early-lung-cancer-100470895",false,"NCT05411809","The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer","Inclusion Criteria:\n\n1. Patients pathologically diagnosed as non-small cell lung cancer, and was early stage（AJCC 8th）;\n2. Patients aged between 18 -80 years; with expected survival time\\>3 months.\n3. Patients with normal organ function within 30 days prior to treatment, the following criteria are met:\n\n   1. blood routine examination criteria : i) hemoglobin (HB) ≥90g\u002FL; ii) absolute neutrophil count (ANC) ≥1.5×10e9\u002FL; iii) platelet (PLT) ≥80×10e9\u002FL; b) biochemical tests meet the following criteria: i) total bilirubin (TBIL) ≤1.5 times of upper limit of normal (ULN); ii) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 ULN; iii) serum creatinine (Cr) ≤1.5 ULN or creatinine clearance (CCr) ≥60mL\u002Fmin;\n\nExclusion Criteria:\n\n1. Patients with small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer);\n2. Patients with factors that affect oral medication (such as cannot swallow, chronic diarrhea and intestinal obstruction, etc.) or intravenous medication;\n3. Patients with any other severe and\u002For uncontrolled disease;\n4. Patients with a history of psychotropic medicine abuse and cannot quit or have mental disorders;\n5. Patients with disease which will severely endanger their security and could not complete this study, according to the judgement of researchers；","ALL","18 Years","80 Years",{"count":63,"type":64},180,"ESTIMATED","INTERVENTIONAL",[67],"NA","The purpose of this study is to determine whether ctDNA could help to evaluate whether to use drug adjuvant therapy after SBRT in patients with early lung cancer.",[70],"Stereotactic Body Radiation Therapy","NOT_YET_RECRUITING","2022-06-06",{"date":74,"type":75},"2022-06-09","ACTUAL",{"date":77,"type":64},"2022-06-15",{"date":79,"type":64},"2027-05-15",{"name":5,"class":6},1]